Michael Kauffman, M.D., Ph.D., Lead Director
Dr. Michael Kauffman is the cofounding CEO of Karyopharm Therapeutics. Previously, he was the Chief Medical Officer of Onyx Pharmaceuticals Inc., where he was a key leader in the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma. Dr. Kauffman was Chairman of Proteolix (now Onyx) prior to becoming CMO and is past President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). He played a key role in the Velcade® Development Program at Millennium Pharmaceuticals, and held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School and is board certified in internal medicine.
Mr. Barberich founded Sepracor, Inc. a publicly-traded, fully integrated research pharmaceutical company, in 1984 and served as CEO and Chairman for more than 20 years. Under his leadership at Sepracor, revenues grew to more than a billion dollars as the company partnered and commercialized a number of successful products, including Allegra®, Clarinex®, Lunesta® and Xopenex®. In 2009, Sepracor, now known as Sunovion, was acquired by Dainippon Sumitomo to form one of the largest Japanese-based global pharmaceutical companies. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation, a major supplier of research tools to the life sciences industry. He also served on the Board of Trustees of Boston Medical Center and the Pharmaceutical Research and Manufacturers’ Association. Mr. Barberich is a graduate of Kings College and holds a Bachelor of Science degree in Chemistry.
Eric Rowinsky, M.D.
Dr. Eric Rowinsky’s professional focus has been on the clinical and registrational strategies of anticancer therapeutics. Currently, Dr. Rowinsky serves as an Executive Director and President at RGenix Inc., a life sciences company focused on discovering new cancer targets using a novel microRNA platform licensed. He is a consulting Chief Medical Officer for Hummingbird Biosciences, which has a novel platform for the unique epitope targeting of monoclonal antibodies and also served as the Chief Scientific Officer of Clearpath Development Co., which rapidly advanced development stage therapeutic assets to pre-defined human Proof-of-Concept milestones. Prior to serving in these capacities, he was the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics (2010-2015). In 2010, Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer until it was acquired in 2011. From 2005 to 2010, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly. Previous to that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Rowinsky is a member of the board of directors of Biogen, Kitov Pharmaceuticals, and Fortress Biosciences, all public life sciences companies, and has served on the board of directors of BIND Therapeutics, a life-science company acquired by Pfizer, and Navidea Biopharmaceuticals, Inc.. He played an integral role in the development and execution of clinical development and registrational strategies resulting in the approval of a wide array of classical cytotoxics, monoclonal antibodies, and targeted therapeutics world-wide. He has authored more than 310 peer-reviewed manuscripts, serves as an editor of several cancer journals.
Brian Stuglik, R.Ph., Chief Executive Officer
Brian Stuglik was appointed to Chief Executive Officer (CEO) of Verastem Oncology in July 2019. Mr. Stuglik is a global leader in the oncology pharmaceutical sector having successfully developed, acquired and launched several important oncology products across multiple tumor types and therapeutic approaches in his more than 30-year career in US and International pharmaceutical development, product strategy, commercialization and business development. He spent the majority of his career at Eli Lilly and Company, culminating in his role as Global Vice President and Chief Marketing Officer, Oncology Global Marketing, advancing Lilly Oncology from a single approved product to a portfolio of marketed or late-stage compounds across more than 10 cancer types. He was a founding member of Proventus Health Solutions, assisting biotech companies integrate development and commercial considerations into a unified approach. He is a member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO). Brian earned his Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.
Bruce Wendel serves as Vice Chairman of the Board of Directors of GT Biopharma, Inc. Mr. Wendel served as Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company. Prior to Hepalink, Mr. Wendel served as Vice Chairman and Chief Executive Officer at Abraxis BioScience, LLC where he oversaw the development and commercialization of Abraxane®. He also led the negotiations that culminated in the acquisition of Abraxis by Celgene in a deal valued at over $2.9 billion. Prior to Abraxis, Mr. Wendel served in business and corporate development roles of increasing responsibility at American Pharmaceutical Partners, IVAX Corporation and Bristol-Myers Squibb. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to global business and corporate development. Mr. Wendel earned a juris doctorate degree from Georgetown University Law School, and a B.S. from Cornell University.
Ms. Consylman currently serves as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, Inc., a commercial biotech company, where she oversees finance, tax, investor relations, communications, corporate strategy and corporate development. She also currently serves as a member of the board of directors of Assembly Biosciences, Inc. Prior to joining Ironwood, Gina was Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation, a healthcare and security technology solutions company, where she led the company’s global accounting and treasury teams. Prior to Analogic, Gina held senior level accounting and corporate controller positions at Biogen Inc. and Varian Semiconductor Equipment Associates, Inc. (acquired by Applied Materials, Inc.). She began her career in public accounting at Ernst & Young LLP. Ms. Consylman holds a Bachelor of Science degree in accounting from Johnson & Wales University, a Master of Science degree in taxation from Bentley University, and is a Certified Public Accountant.
Mr. Johnson is a recognized leader in the pharmaceutical and biotechnology industry with more than three decades of experience. He served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, responsible for the Biotechnology, Immunology and Oncology commercial businesses.
Previously, Mr. Johnson served as president of Eli Lilly & Company’s Worldwide Oncology Unit, following the company’s 2008 acquisition of ImClone Systems, Inc., where he served as Chief Executive Officer and a member of ImClone’s Board of Directors. He has served as a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).
Mr. Johnson also served as Chairman, President and Chief Executive Officer of Dendreon Corporation and has held other executive roles within the biotech industry. Currently, he is a member of the Board of Directors of Strongbridge Biopharma plc (SBBP), BioAgilytix (private) and Mirata Pharmaceuticals (private).